AP NEWS

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018-2020 - ResearchAndMarkets.com

September 7, 2018

DUBLIN--(BUSINESS WIRE)--Sep 7, 2018--The “Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Non Alcoholic Fatty Liver Disease (NAFLD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018′ report provides comprehensive insights about marketed and Phase III products for Non Alcoholic Fatty Liver Disease (NAFLD). The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Coverage of API manufacturers for Non Alcoholic Fatty Liver Disease (NAFLD) marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

This report provides a comprehensive understanding of the emerging Phase III therapies for Non Alcoholic Fatty Liver Disease (NAFLD) which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Scope:

A review of the marketed products for Non Alcoholic Fatty Liver Disease (NAFLD) including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details. Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details API manufacturers for the marketed products with location details Emerging Phase III product profiles for Non Alcoholic Fatty Liver Disease (NAFLD) including product description, developmental activities, licensors & collaborators and chemical information

Key Topics Covered:

1. Report Introduction

2. Non Alcoholic Fatty Liver Disease (NAFLD): Overview

Risk Factors Causes Symptoms Pathophysiology Prognosis Diagnosis Treatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

Product Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Clinical Trials Regulatory Milestones Product Development Activities

5. Emerging Therapies (Phase III)

Product Description Research and Development Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/f9xb88/non_alcoholic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180907005446/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/07/2018 02:44 PM/DISC: 09/07/2018 02:44 PM

http://www.businesswire.com/news/home/20180907005446/en

AP RADIO
Update hourly